7 results
To determine whether addition of selexipag to current PAH therapy improves exercise capacity, imaging parameters and quality of life, delays time-to-first-PAH-related morbidity and mortality, prevents worsening of World Health Organization…
To determine the efficacy endpoint whether the lack of ATP function will cause more appropriate but unnecessary shock therapy in patients with a S-ICD. Furthermore we will study the complication endpoint whether the S-ICD is superior to the TV-ICD…
This research has the goal to determine which treatment is the most effective treatment in terms of prevention of treatment failure, in costs and has the patients preference when comparing PDT, Imiquimod and 5FU.
To explore the efficacy and safety of an oral IP receptor agonist in an inoperable or persistent/recurrent CTEPH population treated with standard of care.
Main objective:To assess the effects of selexipag on right ventricular (RV) function in participants with PAH.Secondary objectives:- To further assess the effects of selexipag on RV function using MRI.- To assess the effects of selexipag on disease…
To establish that recovery time from a bronchoprofocation test is faster with HFNC compared to no interfention
The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).